论文部分内容阅读
目的:探讨绝经后妇女Beta-Crosslaps和PINP的水平变化及固肾健脾方干预的临床效果。方法:选择绝经后骨质疏松症妇女患者85例,随机分为观察组43例,对照组42例。两组均给予钙尔奇D 600 mg口服外,观察组再给予固肾健脾方口服。采用电化学发光免疫测定法分别在治疗前、治疗后3个月和6个月时测定血清中Beta-Crosslaps和PINP的水平变化。结果:观察组在治疗后3个月和6个月时的Beta-Crosslaps和PINP水平均低于治疗前及与同时间段的对照组,其差异有统计学意义(P<0.05);同时,绝经后妇女体质量与Beta-Crosslaps存在负相关的关系。结论:Beta-Crosslaps和PINP能较好地反映绝经后妇女的骨转换情况。而固肾健脾方能在一定程度上减缓骨转换,促进骨形成。
Objective: To investigate the changes of Beta-Crosslaps and PINP levels in postmenopausal women and the clinical effects of Gushen Jianpi Fang intervention. Methods: Eighty-five patients with postmenopausal osteoporosis were randomly divided into observation group (n = 43) and control group (n = 42). Two groups were given calcium Erqi D 600 mg orally, the observation group was given Gushen Jianpi Fang oral. The levels of Beta-Crosslaps and PINP in serum were determined by electrochemiluminescence immunoassay before treatment, 3 months and 6 months after treatment respectively. Results: The levels of Beta-Crosslaps and PINP in the observation group at 3 and 6 months after treatment were lower than those in the control group before and at the same time point (P <0.05). At the same time, Postmenopausal women have a negative correlation with Beta-Crosslaps. Conclusion: Beta-Crosslaps and PINP can better reflect the bone turnover in postmenopausal women. The Gushen Jianpi side to a certain extent, reduce bone turnover, promote bone formation.